6 active not recruiting. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 6 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Glomerulonephritis, IGA: new trials by email Literature Review of Glomerulonephritis, IGA trials Research Report on Glomerulonephritis, IGA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy RG002C0106, placebo subcutaneous administration - IgA Nephropathy (IgAN) | Phase 2 | Active not recruiting | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | 30 | 2025-09-08 | 2026-10-13 |
| A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases SGB-9768 - IgA Nephropathy (IgAN), C3 Glomerulopathy | Phase 2 | Active not recruiting | Suzhou Sanegene Bio Inc. | 45 | 2025-06-06 | 2026-09-04 |
| Monthly Dosing of Atacicept in IgAN Atacicept - IgA Nephropathy (IgAN), Berger Disease | Phase 2 | Active not recruiting | Vera Therapeutics, Inc. | 90 | 2025-05-29 | 2026-04-13 |
| Phase 2b Open-Label Repeat Kidney Biopsy Study Sibeprenlimab - IgA Nephropathy | Phase 2 | Active not recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 56 | 2024-12-05 | 2026-10-27 |
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases Atrasentan - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 103 | 2021-03-15 | 2026-06-01 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Churg-Strauss Syndrome (1) · Diabetic Nephropathies (1) · Glomerulonephritis, Membranous (1) · Glomerulosclerosis, Focal Segmental (1) · Granulomatosis with Polyangiitis (1) · Lupus Nephritis (1) · Microscopic Polyangiitis (1) · Nephritis, Hereditary (1)
Autoimmune Diseases (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Glomerulonephritis (6) · Immune System Diseases (6) · Kidney Diseases (6) · Male Urogenital Diseases (6) · Nephritis (6) · Urogenital Diseases (6) · Urologic Diseases (6) · Connective Tissue Diseases (2) · Skin and Connective Tissue Diseases (2) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1)
Atrasentan (1) · TACI receptor-IgG Fc fragment fusion protein (1)
Alpine Immune Sciences, Inc. (1) · Novartis Pharmaceuticals (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. (1) · Suzhou Sanegene Bio Inc. (1) · Vera Therapeutics, Inc. (1)
United States (4) · Australia (2) · China (2) · South Korea (2) · United Kingdom (2) · Argentina (1) · Canada (1) · Italy (1) · Japan (1) · Puerto Rico (1) · Spain (1)
Zeeshan Khawaja (1)